Advanced therapies for pulmonary hypertension

Advanced therapies for pulmonary hypertension aim to improve survival, functional capacity, and quality of life in patients with elevated pulmonary arterial pressures. This condition results from structural and functional changes in the pulmonary vasculature, leading to right heart strain and progressive respiratory compromise. Symptoms often include exertional shortness of breath, fatigue, chest discomfort, and, in severe cases, syncope. Accurate diagnosis relies on echocardiography, right heart catheterization, imaging studies, and laboratory evaluations to identify the underlying etiology and determine disease severity.

Management with advanced therapies involves pharmacologic, procedural, and supportive strategies. Pulmonary vasodilators—including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs—target abnormal vascular remodeling and improve hemodynamics. In selected cases, interventional procedures such as atrial septostomy or lung transplantation may be indicated. Adjunctive measures, including oxygen therapy, exercise training, and lifestyle modifications, support functional improvement. Multidisciplinary collaboration among pulmonologists, cardiologists, and transplant teams ensures individualized care. Continuous monitoring and patient education on symptom recognition, medication adherence, and activity adjustments are essential for optimizing outcomes in pulmonary hypertension.